Novel insight into mechanisms of ROS1 catalytic activation via loss of the extracellular domain by Kristen Jones, Clare Keddy, Chelsea Jenkins, Katelyn Nicholson, Ujwal Shinde, Monika A. Davare

Get full text

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors by Sudarshan R Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Clare Keddy, Catherine Z Beach, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A Davare

Get full text

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors by Romel Somwar, Nicolle E. Hofmann, Bryan Smith, Igor Odintsov, Morana Vojnic, Irina Linkov, Ashley Tam, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, Daniel Flynn, Marc Ladanyi, Alexander Drilon, Ujwal Shinde, Monika A. Davare

Get full text

ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6-specific nanobody restricts M. tuberculosis growth in macrophages by Timothy A Bates, Mila Trank-Greene, Xammy Nguyenla, Aidan Anastas, Sintayehu K Gurmessa, Ilaria R Merutka, Shandee D Dixon, Anthony Shumate, Abigail R Groncki, Matthew AH Parson, Jessica R Ingram, Eric Barklis, John E Burke, Ujwal Shinde, Hidde L Ploegh, Fikadu G Tafesse

Get full text

Oncogenic <i>NTRK3</i> mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia by Sunil K. Joshi, Ariane Huang, Janét Pittsenbarger, Ujwal Shinde, Camilo Posso, Paul D. Piehowski, Sara J.C. Gosline, Richard D. Press, Marina A. Gritsenko, Chelsea Hutchinson, Karl K. Weitz, Kevin Watanabe-Smith, Nicola Long, Karin D. Rodland, Jeffrey W. Tyner, Brian J. Druker, Cristina E. Tognon

Get full text